Immunotherapy Now First Line for Esophageal Cancer

Nivolumab (Opdivo) with chemotherapy or in combination with ipilimumab (Yervoy) has been approved by the FDA for first-line use in the treatment of unresectable advanced or metastatic esophageal cancer.
FDA Approvals

source https://www.medscape.com/viewarticle/974800?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost